Supernus Pharmaceuticals, Inc.

LSE:0LB2 Stock Report

Market Cap: US$2.1b

Supernus Pharmaceuticals Valuation

Is 0LB2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0LB2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$185.80
Fair Value
79.2% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: 0LB2 ($38.69) is trading below our estimate of fair value ($185.8)

Significantly Below Fair Value: 0LB2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0LB2?

Key metric: As 0LB2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0LB2. This is calculated by dividing 0LB2's market cap by their current earnings.
What is 0LB2's PE Ratio?
PE Ratio35.5x
EarningsUS$59.71m
Market CapUS$2.12b

Price to Earnings Ratio vs Peers

How does 0LB2's PE Ratio compare to its peers?

The above table shows the PE ratio for 0LB2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.7x
HIK Hikma Pharmaceuticals
22.1x11.0%UK£5.1b
ANCR Animalcare Group
35.3xn/aUK£163.5m
GSK GSK
22.8x20.8%UK£57.3b
EAH ECO Animal Health Group
66.4x39.2%UK£43.7m
0LB2 Supernus Pharmaceuticals
35.5x28.0%US$2.1b

Price-To-Earnings vs Peers: 0LB2 is good value based on its Price-To-Earnings Ratio (35.5x) compared to the peer average (36.7x).

Price to Earnings Ratio vs Industry

How does 0LB2's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0LB2 35.5xIndustry Avg. 22.1xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0LB2 is expensive based on its Price-To-Earnings Ratio (35.5x) compared to the European Pharmaceuticals industry average (22x).

Price to Earnings Ratio vs Fair Ratio

What is 0LB2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0LB2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.5x
Fair PE Ratio34.1x

Price-To-Earnings vs Fair Ratio: 0LB2 is expensive based on its Price-To-Earnings Ratio (35.5x) compared to the estimated Fair Price-To-Earnings Ratio (34.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0LB2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$38.69
US$42.80
+10.6%
17.4%US$57.00US$36.00n/a5
Jan ’26US$36.32
US$39.25
+8.1%
6.6%US$43.00US$36.00n/a4
Dec ’25US$36.53
US$39.25
+7.4%
6.6%US$43.00US$36.00n/a4
Nov ’25US$34.42
US$39.25
+14.0%
6.6%US$43.00US$36.00n/a4
Oct ’25US$31.62
US$39.25
+24.1%
6.6%US$43.00US$36.00n/a4
Sep ’25US$34.88
US$40.50
+16.1%
4.5%US$43.00US$38.00n/a4
Aug ’25US$30.23
US$40.50
+34.0%
4.5%US$43.00US$38.00n/a4
Jul ’25US$27.23
US$40.50
+48.7%
4.5%US$43.00US$38.00n/a4
Jun ’25US$26.62
US$40.50
+52.1%
4.5%US$43.00US$38.00n/a4
May ’25US$30.57
US$40.50
+32.5%
4.5%US$43.00US$38.00n/a4
Apr ’25US$33.55
US$40.50
+20.7%
4.5%US$43.00US$38.00n/a4
Mar ’25US$29.55
US$40.50
+37.1%
4.5%US$43.00US$38.00n/a4
Feb ’25US$27.75
US$41.00
+47.7%
5.2%US$43.00US$38.00US$38.694
Jan ’25US$29.43
US$41.00
+39.3%
5.2%US$43.00US$38.00US$36.324
Dec ’24US$27.84
US$41.00
+47.3%
5.2%US$43.00US$38.00US$36.534
Nov ’24US$23.75
US$40.75
+71.6%
4.7%US$43.00US$38.00US$34.424
Oct ’24n/a
US$42.25
0%
6.1%US$45.00US$38.00US$31.624
Sep ’24US$32.36
US$42.25
+30.6%
6.1%US$45.00US$38.00US$34.884
Aug ’24US$30.45
US$42.25
+38.7%
6.1%US$45.00US$38.00US$30.234
Jul ’24US$29.76
US$43.00
+44.5%
7.2%US$46.00US$38.00US$27.234
Jun ’24US$33.17
US$43.00
+29.7%
7.2%US$46.00US$38.00US$26.624
May ’24US$37.48
US$42.75
+14.1%
6.7%US$45.00US$38.00US$30.574
Apr ’24US$36.47
US$42.75
+17.2%
6.7%US$45.00US$38.00US$33.554
Mar ’24US$37.21
US$42.75
+14.9%
6.7%US$45.00US$38.00US$29.554
Feb ’24n/a
US$43.25
0%
7.7%US$47.00US$38.00US$27.754
Analyst Price Target
Consensus Narrative from 5 Analysts
US$43.16
Fair Value
10.4% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 03:22
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Supernus Pharmaceuticals, Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
David BuckB. Riley Securities, Inc.
John TannerCantor Fitzgerald & Co.